Visual Abstract Summary for the ARIES-HM3 Trial Question Can aspirin be safely excluded from an antithrombotic regimen, including a vitamin K antagonist (VKA), in patients with a fully magnetically levitated LVAD, and does this reduce nonsurgical bleeding complications? Design Key … Read More
aspirin
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
STOPDAPT-3 Trial: Prasugrel Monotherapy after PCI
STOPDAPT-3 TrialShort and Optimal Duration of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-3 Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcomes: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the STOPDAPT-3 trial, comparing the outcomes … Read More
ULTIMATE-DAPT: Ticagrelor Monotherapy after ACS
“ULTIMATE-DAPT” trial summary. It presents the results of a clinical trial comparing the use of ticagrelor alone versus the combination of ticagrelor and aspirin following percutaneous coronary intervention (PCI) in patients with Acute Coronary Syndrome (ACS) from month 1 to … Read More
CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS
Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More
T-PASS Trial: A Shift in Post-Stenting Treatment for ACS
T-PASS Trial Summary The management of Acute Coronary Syndrome (ACS) after stenting has been a hot topic for medical researchers for years. The recent T-PASS Trial in 2023 has shed light on the possible advantages of shifting from the conventional … Read More
VOYAGER PAD Trial: Rivaroxaban in PAD after Revascularization
VOYAGER PAD Trial Summary The VOYAGER PAD trial aimed to assess the efficacy and safety of rivaroxaban, a factor Xa inhibitor, in patients with peripheral artery disease (PAD) who had undergone lower-extremity revascularization. Patients with PAD who have undergone revascularization … Read More
WARFASA Trial: Aspirin for Preventing the Recurrence of VTE
WARFASA Trial Summary The WARFASA trial aimed to evaluate the effectiveness of aspirin in preventing recurrent venous thromboembolism (VTE) in patients who had previously experienced an unprovoked VTE event. Approximately 20% of patients with unprovoked VTE experience a recurrence within … Read More
WASID Trial Summary: Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
WASID Trial Summary The WASID trial sought to compare the effectiveness of warfarin and aspirin in the treatment of atherosclerotic intracranial arterial stenosis, a significant cause of stroke. While warfarin is often preferred over aspirin for this condition, the two … Read More
WOEST Trial Summary: Clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing PCI
WOEST Trial Summary The WOEST trial, a groundbreaking study published in The Lancet, has shed light on a significant issue faced by patients undergoing percutaneous coronary intervention (PCI) while taking oral anticoagulants. Traditionally, triple therapy involving aspirin and clopidogrel has … Read More